PCSK9 Inhibitors and CV Risk Reduction

In this two part educational series, entitled PCSK9 inhibitors and CV Risk Reduction: Understanding the Implications, experts discuss how Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a promising strategy for decreasing CV risk in patients. In the first session, Drs. Michael Blaha and Michael Miller discuss The Emerging Role of PCSK9 Inhibitors. In part 2, Drs. Marc S. Sabatine, and James Underberg analyze the PCSK9 Outcome Studies. This series will improve clinician’s knowledge of the updated guidelines and the benefits /risks of newer therapies. It also provides clinicians with the tools to select the optimal LDL-C-lowering regimens, address concerns, and improve adherence, to more effectively lower cardiovascular risk in their patients.

CVD and PCSK9 Inhibitors: Analyzing the Outcome Studies and Understanding Their Implications

James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine

Marc S. Sabatine, MD, MPH
Lewis Dexter, MD
Distinguished Chair in Cardiovascular Medicine

Duration: 60 minutes
Presented on: May 23, 2017

The Emerging Role of PCSK9 Inhibitors and CV Risk Reduction

Michael J. Blaha, MD, MPH
Director of Clinical Research,
Ciccarone Center for the Preventon of Heart Disease

Michael Miller, MD, FACC, FAHA
Professor of Cardiovascular Medicine, Epidemiology & Public Health
University of Maryland School of Medicine

Duration: 60 minutes
Presented on: April 11, 2017

Publish Date: 
Wednesday, September 27, 2017 - 12:00

This page was last updated: Sep 28, 2017